Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Deferred Revenue (2020 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Current Deferred Revenue for 5 consecutive years, with $490000.0 as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue changed N/A to $490000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $490000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $8.6 million for FY2022, 85.78% down from the prior year.
  • Current Deferred Revenue hit $490000.0 in Q3 2025 for IDEAYA Biosciences, down from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $77.6 million in Q1 2021 to a low of $490000.0 in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $28.7 million across 4 years, with a median of $16.6 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: decreased 28.1% in 2021 and later crashed 93.58% in 2023.
  • Year by year, Current Deferred Revenue stood at $60.2 million in 2021, then plummeted by 85.78% to $8.6 million in 2022, then tumbled by 83.2% to $1.4 million in 2023, then plummeted by 65.95% to $490000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for IDYA at $490000.0 in Q3 2025, $1.4 million in Q3 2023, and $2.8 million in Q2 2023.